what would you tell week-1 you about cagrilintide
what would you tell week-1 you about cagrilintide, and I want the answer with the reasoning attached rather than just the conclusion.
Why this compound is not simply another agonist, which is how it gets described everywhere else.
Amylin is co-secreted with insulin and signals satiety through its own receptor complexes. It is a different axis from the incretin system, not a parallel version of it. That is why the combination story is interesting: two mechanisms that address appetite differently, rather than more agonism at one receptor.
It is also why the dosing intuitions people bring from the semaglutide and tirzepatide boards do not transfer. Different receptors, different exposure-response, and no published schedule anybody here can reason from.
Kept a log purely because so few people are logging this one. It is one person and it is not data.
Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.
That is everything I have. The rest is opinion and I have tried to keep it out.
best — the order this archive was captured in
Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.
REDEFINE is the combination programme
Read the combination paper twice before saying anything here. The monotherapy and combination arms tell genuinely different stories.
[removed by moderator]
nothing containing this is approved as a standalone product
The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.
satiety signalling rather than incretin signalling
nausea profile in the combination trials is the thing to read carefully
Which receptor family are you attributing that effect to?
independent purity data on this compound is thin
I would not extrapolate the tolerability profile from the monotherapy arm to the combination. The trials report them separately for a reason.
That result is preclinical. Worth flagging, since the thread has been reading it as human data.